Upregulated CircRNAs With Efficacy in Preclinical <i>In Vivo</i> Models Reveal New Targets for Therapeutic Intervention in Glioma
<h3>Abstract</h3> There is a significant need to improve treatment efficacy for patients with glioma. Therefore, we have analyzed the literature for the role of circular RNAs (circRNAs) with respect to selected pathology-related topics of glioma. We have focused on upregulated circRNAs with efficacy in preclinical <i>in vivo</i> models. The identified circRNAs cover the following topics: Temozolomide (TMZ) resistance, transmembrane and secreted proteins, wingless-related integration site (WNT) signaling, cytoskeleton dynamics, cell-cell and cell-extracellular matrix interactions, as well as circRNAs with additional functions. We describe possible therapeutic tools and challenges with respect to delivery of the corresponding inhibitory agents.
Authors
- Satu Nahkuri (ORCID: https://orcid.org/0000-0002-4011-9319)
- Ulrich H. Weidle
Institutions
- Roche (Switzerland) (CH)
- Roche Pharma AG (Germany) (DE)
Publication Details
- Journal
- Cancer Genomics & Proteomics
- Published
- 2026-06-29
- DOI
- https://doi.org/10.21873/cgp.20591
- Primary Topic
- Circular RNAs in diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00